Scarica l'app Stockscreener
2.31
1.28%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.34
Aprire:
$2.32
Volume 24 ore:
2.77M
Relative Volume:
0.85
Capitalizzazione di mercato:
$1.03B
Reddito:
$69.64M
Utile/perdita netta:
$-26.09M
Rapporto P/E:
-32.31
EPS:
-0.0715
Flusso di cassa netto:
$-38.80M
1 W Prestazione:
+0.87%
1M Prestazione:
-3.75%
6M Prestazione:
+99.14%
1 anno Prestazione:
+115.89%
Intervallo 1D:
$2.245
$2.35
Intervallo di 1 settimana:
$2.16
$2.415
Portata 52W:
$1.02
$2.68
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Nome
Lexicon Pharmaceuticals Inc
Settore
Industria
Telefono
(281) 863-3000
Indirizzo
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
2.31 | 990.56M | 69.64M | -26.09M | -38.80M | -0.0715 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-30 | Iniziato | Leerink Partners | Outperform |
| 2023-03-07 | Iniziato | Jefferies | Hold |
| 2022-08-12 | Iniziato | Piper Sandler | Overweight |
| 2021-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-18 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Downgrade | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-11 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Downgrade | Stifel | Buy → Hold |
| 2019-03-25 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Reiterato | Stifel | Buy |
| 2018-02-23 | Downgrade | Needham | Buy → Hold |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Reiterato | H.C. Wainwright | Buy |
| 2017-03-01 | Reiterato | Wedbush | Outperform |
| 2016-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2016-08-05 | Reiterato | Wedbush | Outperform |
| 2016-08-02 | Iniziato | Citigroup | Buy |
| 2016-03-02 | Reiterato | Wedbush | Outperform |
| 2015-11-09 | Reiterato | Wedbush | Outperform |
| 2015-09-28 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Downgrade | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Downgrade | JP Morgan | Overweight → Neutral |
Mostra tutto
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
Lexicon (LXRX) Completes Patient Randomization in Key Phase 3 Tr - GuruFocus
Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment - marketscreener.com
Lexicon's HCM study spans 20 countries; results anticipated Q1 2027 - Stock Titan
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM) - Yahoo Finance Australia
Lexicon Pharmaceuticals Inc (LXRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Institutional Confidence - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexicon Pharmaceuticals Inc - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
LXRX|Lexicon Pharmaceuticals Inc|Price:2.355|Chg%:+0.065 - TradingKey
Price to sales forward of Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX - TradingView
Lexicon Pharmaceuticals Inc (LXRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
LXRX|Lexicon Pharmaceuticals Inc|Price:2.290|Chg%:-0.010 - TradingKey
Lexicon Pharmaceuticals Inc (LXRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Price to earnings forward of Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX - TradingView
Enterprise value to EBITDA forward of Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX - TradingView
Price to book forward of Lexicon Pharmaceuticals, Inc. – NASDAQ:LXRX - TradingView
Lexicon Pharmaceuticals Inc. (LXRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
What Lexicon Pharmaceuticals (LXRX)'s Broad Russell Index Inclusion Means For Shareholders - simplywall.st
Lexicon Pharmaceuticals outlines its path in gastrointestinal disease. Drug pipeline and Nasdaq list - ad-hoc-news.de
Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rally - ChartMill
Lexicon Pharmaceuticals highlights diabetes drug focus. Strategy matters more than near-term headlin - Ad-hoc-news.de
Lexicon Pharmaceuticals (LXRX) Gains 3.88% as Stock Tests Key ResistanceStop Loss Guidance - DonanımHaber
LXRX News | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Earnings call transcript: Lexicon Pharmaceuticals Q1 2026 sees dramatic revenue surge - Investing.com
Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion - Yahoo Finance
How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX) - simplywall.st
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM: LXRX) added to Russell 2000 Index - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark - marketscreener.com
Lexicon Pharmaceuticals (LXRX) Hovers Near Key Support Amid Flat Trading SessionDark Pool Volume - dars.gov.et
Here's why you should add LXRX stock to your portfolio now - MSN
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Growth Benchmark - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM: LXRX) added to Russell 3000E Index - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000E Growth Benchmark - marketscreener.com
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000 Growth Benchmark - marketscreener.com
LXRX Surges As Traders Pounce On Strong Breakout - StocksToTrade
LXRX Jumps As Traders Focus On Breakout Momentum - timothysykes.com
LXRX Stock Climbs As Bullish Momentum Attracts Short-Term Traders - StocksToTrade
LXRX Climbs As Bulls Press Multi-Day Breakout - timothysykes.com
Lexicon Pharmaceuticals stock hits 52-week high at $2.53 By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals stock hits 52-week high at $2.53 - Investing.com UK
Lexicon Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LXRX) - TradingView
LXRX Forecast — Price Target — Prediction for 2027 - TradingView
Lexicon Pharmaceuticals debuts HCM education booth at heart failure conference - Traders Union
Here's Why You Should Add LXRX Stock to Your Portfolio Now - TradingView
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Lexicon Pharmaceuticals StockSunday background on strategy and trials - AD HOC NEWS
LEXICON PHARMACEUTICALS INC (LXRX) Stock Chart - ChartMill
Lexicon Pharmaceuticals Inc Azioni (LXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lexicon Pharmaceuticals Inc Azioni (LXRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
126,122 |
| SOBECKI CHRISTOPHER J | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
293,177 |
| Cheung Ivan | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
89,312 |
| BARKER SAM L | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
213,771 |
| Amouyal Philippe | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
374,486 |
| DEBBANE RAYMOND | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
1,995,498 |
| Artal Participations S.a r.l. | Director |
Apr 30 '26 |
Option Exercise |
0.00 |
20,421,735 |
0 |
175,156,062 |
| DEBBANE RAYMOND | Director |
Feb 25 '26 |
Buy |
1.49 |
2,000 |
2,980 |
1,906,186 |
| DEBBANE RAYMOND | Director |
Feb 23 '26 |
Buy |
1.47 |
100,000 |
147,000 |
1,904,186 |
| DEBBANE RAYMOND | Director |
Feb 20 '26 |
Buy |
1.48 |
100,000 |
147,790 |
1,804,186 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):